Santa Monica and San Francisco, CA – GoodRx, America’s leading prescription price transparency platform, today announced an investment from Francisco Partners and Spectrum Equity.

"We are proud to offer solutions that help Americans afford life-saving medications,” said Doug Hirsch, co-CEO of GoodRx. “The U.S. healthcare system can be confusing and opaque. We believe every American deserves a clear, simple way to understand and control their healthcare budgets.”

More than 2.5 million people use GoodRx’s website and popular mobile apps each month. GoodRx helps consumers save up to 80% on their medications by delivering prices and available discounts at nearly every pharmacy in the U.S. Thousands of physicians and employees use GoodRx, and its services have been positively reviewed by Good Morning America, the American Heart Association, The New York Times, ABC News, AARP, Forbes and many others.

“The expertise and resources of Francisco Partners and Spectrum Equity will enable GoodRx to provide information and savings to even more Americans,” added Trevor Bezdek, co-CEO of GoodRx.

Francisco Partners has deep experience in the healthcare and pharmacy IT space through its prior investments in such companies as CoverMyMeds, Aesynt, HealthcareSource and Therapeutic Research Center. Spectrum Equity has a track record of investing in leading consumer internet and healthcare IT companies, including Ancestry.com, SurveyMonkey, Lynda.com and Passport Health.

“GoodRx sits at the intersection of two healthcare megatrends: the ‘consumerization’ of healthcare and demand for greater price transparency,” said Chris Adams, Partner at Francisco Partners. “GoodRx has already gained significant traction, and we look forward to partnering with the existing leadership team to further their vision of making prescription medications more affordable for consumers.”

“GoodRx stands out in the healthcare space because it is building a consumer brand and a healthcare tool that Americans want to use,” said Steve LeSieur, Managing Director at Spectrum Equity. “GoodRx has a tremendous opportunity to serve the mass market and make a real impact on the nation’s healthcare spend.”

Financial terms of the transaction were not disclosed.

About GoodRx

GoodRx is the largest prescription price transparency platform in America. The company gathers the most up-to-date prices, co-pays, and discounts on medications from nearly every pharmacy in the country and provides this information to consumers in an easy-to-use mobile and web experience. With GoodRx, Americans can save up to 80% on their prescriptions. A top-ranked medical app in the iTunes App Store, GoodRx can be used by anyone, regardless of their insurance or Medicare status. For more information and to download the free iOS or Android app, visit www.goodrx.com.

About Francisco Partners

Francisco Partners is a leading global private equity firm, which specializes in investments in technology and technology-enabled services businesses. Since its launch over 15 years ago, Francisco Partners has raised approximately $10 billion in capital and invested in more than 150 technology companies, making it one of the most active and longstanding investors in the technology industry. The firm invests in transaction values ranging from $50 million to over $2 billion, where the firm’s deep sectoral knowledge and operational expertise can help companies realize their full potential.

About Spectrum Equity

Founded in 1994 with offices in Boston and San Francisco, Spectrum Equity is a leading growth equity firm providing capital and strategic support to innovative internet, software and information services companies. Representative investments include Ancestry.com, BATS, Definitive Healthcare, GrubHub, Lynda.com, Passport Health, SurveyMonkey and Verafin. For more information, visit www.spectrumequity.com.

Press Contact:

For GoodRx:
Meredith Frazier
mailto:goodrx@bigfishpr.com
617-600-7560

For Francisco Partners:
Alex Stephan
mailto:press@franciscopartners.com
650-801-0947

For Spectrum Equity:
Sard Verbinnen & Co.
Matt Benson / David Isaacs
mailto:mbenson@sardverb.com / mailto:disaacs@sardverb.com
212-687-8080 / 415-618-8750